Aura Biosciences (NASDAQ:AURA - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.09). On average, analysts expect Aura Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Aura Biosciences Stock Up 1.3 %
Shares of NASDAQ AURA traded up $0.08 during mid-day trading on Friday, hitting $6.15. 118,997 shares of the company traded hands, compared to its average volume of 203,062. Aura Biosciences has a 1 year low of $4.84 and a 1 year high of $12.38. The stock has a market capitalization of $308.88 million, a price-to-earnings ratio of -3.55 and a beta of 0.43. The business has a 50 day moving average of $6.31 and a two-hundred day moving average of $7.93.
Wall Street Analysts Forecast Growth
Several research analysts have commented on AURA shares. Lifesci Capital upgraded shares of Aura Biosciences to a "strong-buy" rating in a report on Friday, January 31st. HC Wainwright set a $25.00 price objective on Aura Biosciences in a research note on Tuesday, March 25th. JMP Securities set a $19.00 target price on Aura Biosciences in a research note on Wednesday, March 26th. Finally, Citigroup reiterated an "outperform" rating on shares of Aura Biosciences in a research note on Wednesday, March 26th. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $22.75.
View Our Latest Analysis on Aura Biosciences
Insider Buying and Selling
In other Aura Biosciences news, insider Conor Kilroy sold 7,162 shares of the company's stock in a transaction that occurred on Wednesday, April 16th. The stock was sold at an average price of $5.49, for a total transaction of $39,319.38. Following the completion of the sale, the insider now owns 179,313 shares of the company's stock, valued at $984,428.37. This represents a 3.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders sold 14,148 shares of company stock worth $91,434. Corporate insiders own 5.40% of the company's stock.
About Aura Biosciences
(
Get Free Report)
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Featured Stories
Before you consider Aura Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.
While Aura Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
